IC
ELTX icon

Ikarian Capital’s Elicio Therapeutics ELTX Stock Holding History

Ikarian Capital’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$419K Buy
+107,100
New +$1.08M 0.05% 125

Other funds holding ELTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Ikarian Capital's ELTX Position: Q2 2026 in Review

Ikarian Capital opened a new position in Elicio Therapeutics (ELTX) in Q2 2026: 100,000 shares worth $391K. The stake represents 0.04% of the portfolio and ranks #129 among its holdings.

46 funds tracked by Wall St. Rank hold ELTX as of Q2 2026.

  • Ikarian Capital held 100,000 shares of Elicio Therapeutics worth $391K as of Q2 2026.
  • Elicio Therapeutics was a new Ikarian Capital position in Q2 2026.
  • Elicio Therapeutics made up 0.04% of Ikarian Capital's portfolio in Q2 2026, its #129 holding.
  • 46 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.